Merck (MRK) Assets (2009 - 2026)
Merck's (MRK) quarterly Assets came in at $129.8 billion in Q2 2026, up 10.45% year-over-year from $117.5 billion in Q2 2025, and up 0.87% quarter-over-quarter from $128.7 billion in Q1 2026.
Analysis
Merck (MRK) Assets (2009 - 2026) Analysis & Trends
Merck (MRK) has reported Assets for 18 consecutive years, with $129.8 billion the latest figure, recorded in Q2 2026.
- On a quarterly basis, Assets rose 10.45% year-over-year to $129.8 billion in Q2 2026; TTM through Jun 2026 was $129.8 billion, a 10.45% increase from a year earlier, with the FY2025 full-year figure at $136.9 billion, up 16.87% from the prior year.
- Assets was $129.8 billion for Q2 2026 at Merck, up from $128.7 billion in the prior quarter.
- Over five years, Assets peaked at $136.9 billion in Q4 2025 and troughed at $104.5 billion in Q2 2023.
- A 5-year average of $114.8 billion and a median of $110.9 billion in 2022 frame the typical range for Assets.
- Across the five-year window, Assets gained 18.09% in 2022 and fell 2.45% in 2023, its largest moves.
- Over 5 years, Assets stood at $109.2 billion in 2022, then fell by 2.28% to $106.7 billion in 2023, then rose by 9.78% to $117.1 billion in 2024, then rose by 16.87% to $136.9 billion in 2025, then retreated by 5.16% to $129.8 billion in 2026.
- The last three Assets figures came in at $129.8 billion (Q2 2026), $128.7 billion (Q1 2026), and $136.9 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 201.13 Bn |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 150.01 Bn |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | 4.32 Bn |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 7.87 Bn |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 7.22 Bn |
| 10 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 5.36 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 129.80 Bn |
| Mar 31, 2026 | 128.69 Bn |
| Dec 31, 2025 | 136.87 Bn |
| Sep 30, 2025 | 129.55 Bn |
| Jun 30, 2025 | 117.52 Bn |
| Mar 31, 2025 | 115.12 Bn |
| Dec 31, 2024 | 117.11 Bn |
| Sep 30, 2024 | 117.53 Bn |
| Jun 30, 2024 | 112.63 Bn |
| Mar 31, 2024 | 105.85 Bn |
| Dec 31, 2023 | 106.68 Bn |
| Sep 30, 2023 | 106.73 Bn |
| Jun 30, 2023 | 104.47 Bn |
| Mar 31, 2023 | 107.80 Bn |
| Dec 31, 2022 | 109.16 Bn |
| Sep 30, 2022 | 107.08 Bn |
| Jun 30, 2022 | 107.10 Bn |
| Mar 31, 2022 | 106.67 Bn |
| Dec 31, 2021 | 105.69 Bn |
| Sep 30, 2021 | 93.49 Bn |